Biotech entity
pharma is the sole category represented across all 1 tracked stories. Esperion Therapeutics is most often covered alongside Aardvark Therapeutics, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Esperion Therapeutics, all published on March 6, 2026.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Esperion Therapeutics is most often covered alongside Aardvark Therapeutics, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Esperion Therapeutics, all published on March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Esperion Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Ascendis Pharma achieves a landmark FDA approval for its hypoparathyroidism treatment, while the broader sector sees volatility as Aardvark Therapeutics faces a clinical hold and Theravance Biopharma initiates workforce reductions. Esperion Therapeutics shifts to an aggressive commercial stance following a significant financial resolution.
Esperion Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
